Acute Ischemic Stroke - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Acute Ischemic Stroke - Pipeline Review, H1 2016', provides an overview of the Acute Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke - The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects - The report assesses Acute Ischemic Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Acute Ischemic Stroke Overview 9 Therapeutics Development 10 Pipeline Products for Acute Ischemic Stroke - Overview 10 Acute Ischemic Stroke - Therapeutics under Development by Companies 11 Acute Ischemic Stroke - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Acute Ischemic Stroke - Products under Development by Companies 16 Acute Ischemic Stroke - Companies Involved in Therapeutics Development 18 AB Science SA 18 AstraZeneca Plc 19 Biogen, Inc. 20 D-Pharm Ltd. 21 Daiichi Sankyo Company, Limited 22 DiaMedica Inc. 23 Digna Biotech, S.L. 24 Glucox Biotech AB 25 Grifols, S.A. 26 Lumosa Therapeutics Co., Ltd. 27 Mitsubishi Tanabe Pharma Corporation 28 Pharmicell Co., Ltd. 29 PhytoHealth Corporation 30 Remedy Pharmaceuticals, Inc. 31 Saneron CCEL Therapeutics, Inc. 32 Simcere Pharmaceutical Group 33 Stemedica Cell Technologies, Inc. 34 Acute Ischemic Stroke - Therapeutics Assessment 35 Assessment by Monotherapy Products 35 Assessment by Target 36 Assessment by Mechanism of Action 38 Assessment by Route of Administration 40 Assessment by Molecule Type 42 Drug Profiles 44 3K3A-APC - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 ApTLR-4FT - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Cellgram-IS - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 DB-017 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 DM-199 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 DS-1040 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 glyburide - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 HBI-002 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 HBN-1 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 LT-3001 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 masitinib - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 MP-124 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 natalizumab - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 PHN-014 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Rejuveinix - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 SIM-071201 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 TAL-0500018 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 THR-18 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 ticagrelor - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 TMS-007 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Acute Ischemic Stroke - Recent Pipeline Updates 87 Acute Ischemic Stroke - Dormant Projects 117 Acute Ischemic Stroke - Discontinued Products 119 Acute Ischemic Stroke - Product Development Milestones 121 Featured News & Press Releases 121 Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia 121 Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial 121 Nov 04, 2015: DiaMedica Provides Corporate Update 122 Oct 09, 2015: Remedy Pharmaceuticals' Drug CIRARA
List of Tables
Number of Products under Development for Acute Ischemic Stroke, H1 2016 10 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 (Contd..1) 17 Acute Ischemic Stroke - Pipeline by AB Science SA, H1 2016 18 Acute Ischemic Stroke - Pipeline by AstraZeneca Plc, H1 2016 19 Acute Ischemic Stroke - Pipeline by Biogen, Inc., H1 2016 20 Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H1 2016 21 Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 22 Acute Ischemic Stroke - Pipeline by DiaMedica Inc., H1 2016 23 Acute Ischemic Stroke - Pipeline by Digna Biotech, S.L., H1 2016 24 Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H1 2016 25 Acute Ischemic Stroke - Pipeline by Grifols, S.A., H1 2016 26 Acute Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2016 27 Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 28 Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H1 2016 29 Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H1 2016 30 Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016 31 Acute Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H1 2016 32 Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2016 33 Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 34 Assessment by Monotherapy Products, H1 2016 35 Number of Products by Stage and Target, H1 2016 37 Number of Products by Stage and Mechanism of Action, H1 2016 39 Number of Products by Stage and Route of Administration, H1 2016 41 Number of Products by Stage and Molecule Type, H1 2016 43 Acute Ischemic Stroke Therapeutics - Recent Pipeline Updates, H1 2016 87 Acute Ischemic Stroke - Dormant Projects, H1 2016 117 Acute Ischemic Stroke - Dormant Projects (Contd..1), H1 2016 118 Acute Ischemic Stroke - Discontinued Products, H1 2016 119 Acute Ischemic Stroke - Discontinued Products (Contd..1), H1 2016 120
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]sights.com
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.